BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 5, 2026
Home » Authors » Ronald Trahan

Ronald Trahan

Articles

ARTICLES

European VCs are bullish about health technology

Sep. 28, 2011
By Ronald Trahan

Disruptive cardio technologies attracting investors' attention

March 23, 2011
By Ronald Trahan

Disruptive technology makes debut at OneMedForum 2011

Jan. 17, 2011
By Ronald Trahan

CEOs are bullish about going public and launching in Europe

Jan. 12, 2011
By Ronald Trahan

Stent experts explore device development options, controversy

Sep. 25, 2009
By Ronald Trahan

Polymers and medical devices are focal point for chemists

Aug. 23, 2007
By Ronald Trahan

Larger financing rounds being raised on higher valuations

March 23, 2006
By Ronald Trahan

Boston MedTech Congress: Larger financing rounds being raised on higher valuations

March 20, 2006
By Ronald Trahan

Neurotech leaders gather at 3rd annual industry symposium

Oct. 1, 2003
By Ronald Trahan
View All Articles by Ronald Trahan

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • Antibodies

    Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal

    BioWorld
    Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
  • Breast anatomy

    Unique trial strategy muddies the ODAC waters for camizestrant

    BioWorld
    Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
  • Pancreas

    Sonire starts US study of cancer HIFU after $18M series A

    BioWorld
    Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing